Review of the literature on reference pricing.

This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strategy for cost containment of expenditure on drugs is analyzed as part of the procurement mechanism. We review the existing literature and the state-of-the-art regarding RP by focusing on its economic effects. In particular, we consider: (1) the institutional context and problem-related factors which appear to underline the need to implement an RP strategy; i.e. its nature, characteristics and the sort of health care problems commonly addressed; (2) how RP operates in practice; that is, how third party-payers (the insurers/buyers) have established the RP systems existing on the international scene (i.e. information methods, monitoring procedures and legislative provisions); (3) the range of effects resulting from particular RP strategies (including effects on choice of appropriate pharmaceuticals, insurer savings, total drug expenditures, prices of referenced and non-referenced products and dynamic efficiency; (4) the market failures which an RP policy is supposed to address and the main advantages and drawbacks which emerge from an analysis of its effects. Results suggest that RP systems achieve better their postulated goals (1) if cost inflation in pharmaceuticals is due to high prices rather than to the excess of prescription rates, (2) when the larger is the existing difference in prices among equivalent drugs, and (3) more important is the actual market for generics.

[1]  M. A. Walker,et al.  Healthy Incentives: Canadian Health Reform in an International Context , 1997 .

[2]  J. V. Reenen,et al.  Regulating Drug Prices: Where Do We Go from Here? , 1998 .

[3]  M. Dickson,et al.  Pharmaceutical reference prices. How do they work in practice? , 1998, PharmacoEconomics.

[4]  Lewis Evans,et al.  Money and Medicines: An Economic Analysis of Reference Pricing and Related Public-sector Cost-containment Systems for Pharmaceuticals with Special Reference to New Zealand, by Alan Woodfield, John Fountain and Pim Borren (a review) , 1998 .

[5]  M. Drummond,et al.  The role of economic evaluation in the pricing and reimbursement of medicines. , 1997, Health policy.

[6]  Frederic M. Scherer,et al.  Industry structure, strategy, and public policy , 1996 .

[7]  The Norwegian Health Care System , 1998 .

[8]  P. Olley,et al.  The Canadian Cardiovascular Society and reference-based drug pricing. , 1998, The Canadian journal of cardiology.

[9]  G. Fattore,et al.  The new pharmaceutical policy in Italy. , 1998, Health policy.

[10]  B. O'brien,et al.  Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare , 1996 .

[11]  R. Woollard.  Opportunity lost: a frontline view of reference-based pricing. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  E. Kolassa.  Physicians ' Perceptions of Prescription Drug Prices:: Their Accuracy and Effect on the Prescribing Decision , 1995 .

[13]  J. Hellerstein,et al.  The importance of the physician in the generic versus trade-name prescription decision. , 1998, The Rand journal of economics.

[14]  Hans Granum,et al.  The norwegian experience , 1987 .

[15]  Pricing, Patent Loss and the Market for Pharmaceuticals , 1991 .

[16]  R. Zeckhauser,et al.  The Australian Pharmaceutical Subsidy Gambit: Transmuting Deadweight Loss and Oligopoly Rents to Consumer Surplus , 1991 .

[17]  S. Soumerai,et al.  Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia , 1994 .

[18]  R. Lindsey,et al.  National Pharmacare, Reference-Based Pricing, and Drug R&D: A Critique of the National Forum on Health's Recommendations for Pharmaceutical Policy , 1999 .

[19]  G. Selke,et al.  The German experience in reference pricing. , 1998, Health policy.

[20]  A. P. Boulet,et al.  Reference-based pricing in British Columbia: implications for cardiologists--an analysis. , 1997, The Canadian journal of cardiology.

[21]  R. Beneke.  The German situation , 2000, British journal of sports medicine.

[22]  S B Soumerai,et al.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. , 1991, The New England journal of medicine.

[23]  Fiona M. Scott Morton.  The Interaction between a Most-Favored-Customer Clause and Price Dispersion: An Empirical Examination of the Medicaid Rebate Rules of 1990 , 1997 .

[24]  S. Schneeweiss,et al.  What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? , 1998, Health policy.

[25]  P. Danzon,et al.  Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU , 1997 .

[26]  J. Mann,et al.  The impact of reference pricing on clinical lipid control. , 1998, The New Zealand medical journal.

[27]  C. F. Phillips.  Industrial Market Structure and Economic Performance , 1971 .

[28]  Fiona M. Scott Morton.  The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules , 1997 .

[29]  P. Kanavos,et al.  Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. , 1997, Health policy.

[30]  M. Mcgregor.  Coverage of drug costs: reference-based pricing. , 1998, The Canadian journal of cardiology.

[31]  T. Iversen,et al.  THE NORWEGIAN HEALTH CARE SYSTEM ECONOMICS DEPARTMENT WORKING PAPERS N0. 198 , 1998 .

[32]  P. Danzon.  Pharmaceutical Price Regulation: National Policies Versus Global Interests , 1997 .

[33]  Richard E. Caves,et al.  Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .

[34]  F. Scherer,et al.  Industrial Market Structure and Economic Performance. , 1971 .

[35]  Mclaughlin Pr,et al.  The Canadian Cardiovascular Society and reference-based drug pricing. , 1998 .

[36]  J. Schulenburg.  Management of cost and utilization of pharmaceuticals in Germany , 1997 .

[37]  Frederic M. Scherer,et al.  Pricing, Profits, and Technological Progress in the Pharmaceutical Industry , 1993 .

[38]  Elias Mossialos,et al.  Cost containment and health care reform: a study of the European Union. , 1994, Health policy.

[39]  P. Zweifel,et al.  Price regulation of drugs: Lessons from Germany , 1996 .

[40]  R. Levy.  Prescription cost sharing: economic and health impacts, and implications for health policy. , 1992, PharmacoEconomics.

[41]  D. Salkever,et al.  "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .

[42]  D. J. Gross,et al.  International Pharmaceutical Spending Controls: France, Germany, Sweden, and the United Kingdom , 1994, Health care financing review.